An investor in NYSE:TARO shares filed a lawsuit over alleged violations of Federal Securities Laws by Taro Pharmaceutical Industries Ltd..
Investors who purchased shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) have certain options and for certain investors are short and strict deadlines running. Deadline: December 26, 2016. NYSE:TARO investors should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The plaintiff claims that between July 3, 2014 and September 9, 2016 the defendants made false and/or misleading statements and/or failed to disclose that since 2014 Taro Pharmaceutical has colluded with other pharmaceutical companies to keep the price of generic products artificially high, that the foregoing conduct violated federal antitrust laws, that in turn, Taro Pharmaceutical’s revenues during the Class Period were the result of illegal conduct, and that as a result, Taro Pharmaceutical’s public statements were materially false and misleading at all relevant times.
On September 9, 2016, Taro Pharmaceutical Industries Ltd. disclosed it and two of its senior officers received grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing. Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) declined from $145.20 per share in August 2016 to as low as $92.28 per share on November 3, 2016.
Those who purchased NYSE:TARO shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego